FDA approves anti-bleeding drug from CSL

01/19/2009 | Reuters

The FDA granted clearance for CSL's Riastap, an intravenous drug derived from human plasma that treats a bleeding disorder called congenital fibrinogen deficiency. The approval was based on results from a clinical study that reported improved clot firmness in 14 out of 15 participants, the agency said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ